Penumbra INC Form 4 insider transactions

Penumbra CEO Adam Elsesser donated 77,000 shares of common stock to a charitable organization.

Penumbra, Inc. announced that its stockholders overwhelmingly approved the merger agreement with Boston Scientific Corporation at a special meeting held on May 6, 2026.

Penumbra Inc. urges stockholders to vote FOR the proposed merger with Boston Scientific Corporation, emphasizing the importance of their vote for the upcoming Special Meeting.

Boston Scientific confirms its commitment to the Penumbra acquisition during its Q1 2026 earnings call, targeting a second-half 2026 close.

Penumbra, Inc. is urging its stockholders to vote in favor of the proposed merger with Boston Scientific Corporation at the upcoming Special Meeting on May 6, 2026.

Director Harpreet Grewal sold 100 shares of Penumbra Inc stock on April 2, 2026, under a pre-arranged trading plan.

Penumbra Inc.'s President, Shruthi Narayan, had 117 shares withheld for tax obligations related to restricted stock unit vesting.

Penumbra Inc.'s EVP, General Counsel, and Secretary, Johanna Roberts, disposed of 186 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Penumbra Inc.'s Chief Financial Officer, Maggie Yuen, had 186 shares withheld to cover tax obligations related to restricted stock unit vesting.

Penumbra's Chief Accounting Officer, Lambert Shiu, disposed of 150 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Penumbra's Chief Financial Officer, Maggie Yuen, sold 2,432 shares of common stock for $342.3 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Penumbra Inc. director Harpreet Grewal received 589 restricted stock units with a vesting schedule tied to continued service and a potential merger event.

Penumbra Inc. director Arani Bose was granted 589 restricted stock units, with vesting tied to service and potential acceleration upon a merger with Boston Scientific.

Penumbra Director Janet Leeds was granted 589 restricted stock units, which vest quarterly or upon the closing of a merger with Boston Scientific Corporation.

Penumbra Inc. Director Bridget O'Rourke reported the acquisition of 589 restricted stock units, with vesting tied to continued service and a potential merger with Boston Scientific Corporation.

Penumbra Inc. Director Surbhi Sarna reported the acquisition of 589 common stock units as part of an equity compensation plan.

Penumbra Director Thomas Wilder acquired 589 restricted stock units, subject to a vesting schedule and potential accelerated vesting upon a merger with Boston Scientific.

Penumbra's EVP, General Counsel & Secretary, Johanna Roberts, received two grants of restricted stock units, with accelerated vesting tied to a potential merger with Boston Scientific.

Penumbra's CFO, Maggie Yuen, reported recent RSU grants and tax-related share dispositions, with accelerated vesting tied to a potential merger with Boston Scientific.

Penumbra's Chief Accounting Officer, Lambert Shiu, increased direct beneficial ownership through RSU grants, with accelerated vesting tied to a potential merger with Boston Scientific.

Penumbra Inc.'s President, Shruthi Narayan, reported recent restricted stock unit grants and shares withheld for tax obligations.

Boston Scientific reports strong Q4 2025 results, driven by cardiovascular growth, and reaffirms its long-term targets, emphasizing the strategic acquisition of Penumbra.

Boston Scientific announced a definitive agreement to acquire Penumbra for $14.5 billion in cash and stock, aiming to become a neurovascular leader.

Penumbra Inc. President Shruthi Narayan disposed of 286 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Penumbra, Inc. announced a definitive agreement to be acquired by Boston Scientific Corporation, with the transaction expected to close in 2026.

Boston Scientific Corporation announced a definitive agreement to acquire Penumbra, Inc., a leader in mechanical thrombectomy and neurovascular therapies, on January 15, 2026.

Boston Scientific Corporation announced an agreement to acquire Penumbra, a medical technology company specializing in neurovascular and mechanical thrombectomy, for $15 billion in cash and stock.

Boston Scientific Corporation has entered into a definitive merger agreement to acquire Penumbra, Inc., with Penumbra shareholders receiving a mix of cash and Boston Scientific stock.

Penumbra, Inc. announced a definitive agreement to be acquired by Boston Scientific Corporation for $374 per share in a mix of cash and stock, with the transaction expected to close in 2026.

Boston Scientific Corporation announced a definitive agreement to acquire Penumbra, Inc. for an enterprise value of approximately $14.5 billion, expanding its cardiovascular and neurovascular portfolios.